Camber Spine Continues to Add to its “All Angles” Product Portfolio with Latest Patent Approval

Camber Spine, a leading innovator in spine and medical technologies has announced that it has received a notice of allowance from the United States Patent and Trademark Office (USPTO) for its Variant Retractor technology, bringing the company’s total patent portfolio to 47 patents.

The Variant Retractor is a tool designed to provide flexible spacing support for a variety of spine surgical approaches.

“As our IP portfolio continues to grow, so too does the positive impact we can make for our surgeon customers and their patients,” said Camber Spine Co-Founder and CEO, Daniel Pontecorvo.  “With this latest patent grant from the USPTO, we have now received 47 issued patents, further strengthening our value proposition of offering a broad selection of tools to surgeons that accommodate spine surgery approaches and techniques from literally every possible angle.”

“We are extremely proud of our engineering and manufacturing teams for creating such a robust collection of devices,” added Pontecorvo, “all with the highest structural integrity and quality standards, and we look forward to the remainder of 2022 and a pipeline full of additional product offerings.”

With further expansions to its lines of award-winning Spira and Enza technology platforms due later this year, along with training labs and educational programs to support ALIF, LLIF, OLIF, PLIF and TLIF spine surgery techniques, the company is focused on fulfilling its mission to support the full array of surgical approaches.

The Camber Spine collection of devices will be on display at the American Association of Neurological Surgeons (AANS) Annual Meeting at the Pennsylvania Convention Center (booth #204 on the exhibit floor.  Camber’s booth will also be hosting a series of focus sessions:

  • “Posterior Approach” April 30 at 10:00am;
  • “Advanced Biologics” April 30 at 1:00pm; and
  • “Anterior Column” May 1 at 10:00am.

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”